Core Viewpoint - Rosen Law Firm is urging investors of DexCom, Inc. to take action before the December 29, 2025 deadline for a securities class action related to misleading statements made by the company during the class period from July 26, 2024, to September 17, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified class period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the lead plaintiff deadline of December 29, 2025, and can do so by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4].

Core Insights - Sands Capital Select Growth Strategy reported a portfolio return of 6.3% in Q3 2025, underperforming the benchmark's 10.5% gain, driven by strong corporate earnings and AI enthusiasm [1] - DexCom, Inc. (NASDAQ:DXCM) faced a one-month return of -8.29% and a 52-week decline of 19.94%, closing at $62.53 with a market cap of $24.52 billion [2][3] Company Performance - DexCom, Inc. is a leading producer of glucose monitors, experiencing stock price pressure due to industry weakness and scrutiny over product reliability [3] - Despite challenges, DexCom has shown accelerating year-over-year revenue growth for three consecutive quarters, with Q3 2025 global revenue reaching $1.21 billion, up from $994 million in Q3 2024 [4] Future Outlook - Management raised 2025 revenue guidance cautiously, which disappointed investors, but this conservative approach may allow for upside potential in the latter half of 2025 [3] - Potential catalysts for DexCom include strong adoption of its new 15-day sensor, expanded Medicare coverage, and clarity on long-term plans, with expectations for margin leverage contributing to profitability in 2026 [3]

Core Viewpoint - The Rosen Law Firm is reminding investors of DexCom, Inc. about an important deadline related to a securities class action lawsuit, encouraging them to secure legal counsel before December 29, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users [5]. - The defendants are accused of making false statements regarding the reliability and functionality of the G7 devices, leading to increased regulatory scrutiny and potential legal repercussions for DexCom [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - To join the class action, investors can visit the provided link or contact the firm directly for more information [3][6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 29, 2025 [3][5]. - The lawsuit claims that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which posed health risks to users [5]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom's design changes rendered the G6 and G7 systems less reliable, overstating the devices' enhancements and functionality [5]. - It is claimed that DexCom downplayed the severity of issues related to the G7 devices, which increased the risk of regulatory scrutiny and potential legal repercussions [5]. - The public statements made by DexCom during the Class Period are described as materially false and misleading, leading to investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].

Core Viewpoint - Class actions have been initiated on behalf of stockholders of DexCom, Inc. and Wildermuth Fund, with deadlines for investors to petition the court to serve as lead plaintiff [1]. DexCom, Inc. (NASDAQ:DXCM) - The class action alleges that during the class period from January 8, 2024, to September 17, 2025, DexCom made materially false and misleading statements regarding its business and compliance policies [6]. - Specific allegations include unauthorized design changes to the G6 and G7 devices that rendered them less reliable, presenting health risks to users [6]. - The complaint claims that the enhancements to the G7 were overstated and that the true scope of issues with the devices was downplayed, leading to increased regulatory scrutiny and potential legal and financial harm [6]. Wildermuth Fund (NASDAQ:WEFCX, NASDAQ:WESFX, NASDAQ:WEIFX) - The class action for Wildermuth Fund covers the period from November 1, 2020, to June 29, 2023, with a lead plaintiff deadline of December 29, 2025 [6]. - Allegations include miscalculating the fair value of the Fund's investments and failing to disclose financial support for portfolio companies with questionable viability [6]. - The complaint also states that the Fund intentionally inflated its net asset value, resulting in excessive advisory fees, which harmed class members [6].

Core Viewpoint - Rosen Law Firm is reminding investors of DexCom, Inc. about the upcoming deadline for a securities class action lawsuit, encouraging them to secure legal counsel before December 29, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the lead plaintiff deadline of December 29, 2025, and can join by submitting a form or contacting the law firm [3][6]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues, leading to increased regulatory scrutiny and potential legal repercussions [5].

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. alleging that the company made misleading statements regarding the reliability and safety of its G6 and G7 glucose monitoring devices, which were modified without FDA approval, leading to health risks for users [2][4]. Summary by Sections Lawsuit Details - The lawsuit claims that DexCom made unauthorized design changes to the G6 and G7 devices, which compromised their reliability and presented health risks to users [2]. - Allegations include overstating the enhancements and reliability of the G7, downplaying the severity of issues with the devices, and exposing the company to increased regulatory scrutiny and potential legal consequences [2]. Regulatory Concerns - On March 7, 2025, DexCom received a warning letter from the FDA regarding manufacturing and quality management issues, resulting in a share price drop of $7.12, or approximately 9.15%, from $77.84 to $70.72 [3]. - The FDA's published warning letter on March 25, 2025, confirmed that DexCom had adulterated its devices, leading to a further decline in share price by $1.77, or about 2.4%, from $75.32 to $73.55 [4]. Market Reactions - On September 8, 2025, Oppenheimer downgraded DexCom's rating to "perform" from "outperform," citing concerns over the G7's accuracy and performance, which caused a decline in share price by $2.51, or approximately 3.1%, from $80.51 to $78.00 [5]. - A report by Hunterbrook Media LLC on September 18, 2025, highlighted severe health risks associated with the G7 devices, linking them to hospitalizations and fatalities, resulting in a significant share price drop of $8.33, or about 11%, from $75.78 to $67.45 [7].

Core Viewpoint - Labaton Keller Sucharow LLP has filed a securities class action lawsuit against DexCom, Inc. and certain executives, alleging misleading statements regarding the reliability and safety of their continuous glucose monitoring systems [1][4]. Summary by Sections Lawsuit Details - The lawsuit was filed on November 25, 2025, on behalf of the Boston Retirement System against DexCom and its executives, asserting claims under the Securities Exchange Act of 1934 [1]. - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025 [1]. Allegations - The complaint alleges that DexCom made unauthorized design changes to its CGM products, which rendered them less reliable and posed health risks to users [4]. - It is claimed that these undisclosed issues led to increased regulatory scrutiny and negatively impacted the company's sales and public statements regarding product reliability [4]. Impact on Stock Price - Following disclosures about the accuracy problems of DexCom's CGM devices, the company's stock price fell by $8.99 per share, or 11.8%, closing at $67.45 on September 19, 2025 [5]. Legal Representation - The Boston Retirement System is represented by Labaton Keller Sucharow LLP, which has a strong reputation in securities litigation and manages over $4.5 trillion in assets [8].

Core Insights - DexCom Inc. is recognized as a strong stock within the QQQ index, despite recent price target reductions by analysts [1][2] - The company reported a significant year-over-year revenue increase, but faced challenges with gross margins [3][4] Financial Performance - DexCom achieved $1.21 billion in worldwide revenue for Q3 2025, reflecting a 22% increase year-over-year and 20% organic growth [3] - The company reported a net income of $242.5 million, translating to an earnings per share (EPS) of $0.61, marking the highest quarterly EPS in its history [3] Margin and Guidance Adjustments - Despite record revenue, DexCom's gross profit margin declined to 61.3% from 63% in Q3 2024, attributed to higher-than-expected scrap rates in manufacturing [4] - The company revised its 2025 non-GAAP gross profit margin guidance to approximately 61% while raising its overall revenue guidance to a range of $4.630 to $4.650 billion [4] Analyst Ratings - Morgan Stanley reduced its price target for DexCom to $63 from $89 but maintained an Overweight rating [1] - Truist lowered its price target to $82 from $94, citing a modest earnings beat and weaker-than-expected gross margins [2]

Core Viewpoint - Carillon Tower Advisers' "Carillon Eagle Mid Cap Growth Fund" reported a continued rally in equity markets during Q3 2025, driven by AI enthusiasm, limited inflationary effects from tariffs, and expectations for interest rate cuts from the U.S. Federal Reserve [1] Market Performance - The Russell Midcap Growth Index increased by 2.78%, while the Russell Midcap® Value Index outperformed with a gain of 6.16% during the same quarter [1] Sector Insights - The investor letter provided detailed insights on various sectors including Cyclicals, Healthcare, Information Technology, Financials, and Consumer sectors [1] Company Focus: DexCom, Inc. - DexCom, Inc. (NASDAQ:DXCM) is highlighted as a key stock, known for its continuous glucose monitoring systems, but has faced challenges including a one-month return of -10.14% and a 52-week loss of 20.18% [2][3] - As of November 24, 2025, DexCom's stock closed at $62.21, with a market capitalization of $24.396 billion [2] Financial Performance of DexCom - DexCom reported global revenue of $1.21 billion in Q3 2025, an increase from $994 million in Q3 2024, indicating a positive revenue trend despite recent challenges [4] Concerns and Market Position - There are concerns regarding accuracy issues with DexCom's latest G7 continuous glucose monitor, which may impact its brand and market share [3] - Despite the potential of DexCom as an investment, the company is viewed as having less upside compared to certain AI stocks [4]